Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

被引:10
作者
Pan, Rui [1 ]
Cheng, Jinping [2 ]
Lai, Kelin [1 ]
Huang, Qing [3 ]
Wu, Hui [1 ]
Tang, Yamei [2 ]
机构
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金
国家重点研发计划;
关键词
Intracranial hemorrhage; Vitamin K antagonists; Prothrombin complex concentrate; Meta-analysis; FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; ANTICOAGULATION REVERSAL; WARFARIN; GUIDELINES; MANAGEMENT; COAGULOPATHY; ENLARGEMENT;
D O I
10.1007/s10072-019-3726-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 50 条
[21]   Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis [J].
AlKherayf, Fahad ;
Xu, Yan ;
Gandara, Esteban ;
Westwick, Harrison ;
Moldovan, Ioana Doina ;
Wells, Philip S. .
THROMBOSIS RESEARCH, 2016, 144 :152-157
[22]   Hemostasis Using Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: Systematic Review with Meta-Analysis [J].
Li, Jun-Ping ;
Li, Van ;
Li, Bing ;
Bian, Chang-He ;
Zhao, Feng .
BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY, 2024, 39 (02)
[23]   Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists A meta-analysis [J].
Dentali, Francesco ;
Marchesi, Chiara ;
Pierfranceschi, Matteo Giorgi ;
Crowther, Mark ;
Garcia, David ;
Hylek, Elaine ;
Witt, Daniel M. ;
Clark, Nathan P. ;
Squizzato, Alessandro ;
Imberti, Davide ;
Ageno, Walter .
THROMBOSIS AND HAEMOSTASIS, 2011, 106 (03) :429-438
[24]   Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis [J].
Milioglou, Ioannis ;
Farmakis, Ioannis ;
Neudeker, Mandy ;
Hussain, Zeeshan ;
Guha, Avirup ;
Giannakoulas, George ;
Kotoula, Vassiliki ;
Papaioannou, Maria .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (04) :1137-1150
[25]   Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies [J].
Guo, Zongwen ;
Ding, Xiaoli ;
Ye, Zi ;
Chen, Weiling ;
Chen, Yijian .
CLINICAL CARDIOLOGY, 2021, 44 (07) :917-924
[26]   Risk Factors for Anticoagulant-Associated Intracranial Hemorrhage: A Systematic Review and Meta-analysis [J].
Zeng, Zhiwei ;
Chen, Jiana ;
Qian, Jiafen ;
Ma, Fuxin ;
Lv, Meina ;
Zhang, Jinhua .
NEUROCRITICAL CARE, 2023, 38 (03) :812-820
[27]   Four-Factor Prothrombin Complex Concentrate Versus Plasma for Urgent Vitamin K Antagonist Reversal New Evidence [J].
Sarode, Ravi .
CLINICS IN LABORATORY MEDICINE, 2014, 34 (03) :613-+
[28]   Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0 [J].
Zemrak, Wesley R. ;
Smith, Kathryn E. ;
Rolfe, Stephen S. ;
May, Teresa ;
Trowbridge, Robert L. ;
Hayes, Timothy L. ;
Grindlinger, Gene A. ;
Seder, David B. .
NEUROCRITICAL CARE, 2017, 27 (03) :334-340
[29]   A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy [J].
Khorsand, Nakisa ;
Kooistra, Hilde A. M. ;
van Hest, Reinier M. ;
Veeger, Nic J. G. M. ;
Meijer, Karina .
THROMBOSIS RESEARCH, 2015, 135 (01) :9-19
[30]   Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis [J].
DiRisio, Aislyn C. ;
Harary, Maya ;
Muskens, No S. ;
Yunusa, Ismaeel ;
Gormley, William B. ;
Aglio, Linda S. ;
Smith, Timothy R. ;
Connors, Jean M. ;
Mekary, Rania A. ;
Broekman, Marike L. D. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 62 :188-194